Geneva, Sept. 21 -- International Clinical Trials Registry received information related to the study (NCT07812493) titled 'Pirtobrutinib Plus Methotrexate-Based Chemoimmunotherapy for Systemic DLBCL With CNS Involvement' on Sept. 4.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Pengpeng Xu
Condition:
Pirtobrutinib
Immunochemotherapy
DLBCL - Diffuse Large B Cell Lymphoma
CNS Involvement of Systemic Lymphoma
Intervention:
Drug: pirtobrutinib+MTX+immunolchemotherapy
Recruitment Status: Not recruiting
Phase: Phase 2
Date of First Enrollment: September 1, 2026
Target Sample Size: 24
Countries of Rec...